Targeting the epidermal growth factor receptor in solid tumors: focus on safety

Abstract

Introduction: Inhibition of the EGFR has emerged as a promising anticancer strategy, offering improved efficacy and quality of life for patients affected by tumors. The overall level of toxicity associated with EGFR inhibitors is low compared to other chemotherapy drugs, although they are commonly associated with skin and gastrointestinal adverse events. Thus, patients' quality of life may be considerably affected both by a physical and a psychosocial perspective. Adverse events that lead to treatment interruption or cessation may significantly compromise their outcome.

Areas covered: This review summarizes the characteristics of the distinctive toxicities of drugs targeting EGFR, addressing their incidence, pathophysiology and clinical presentation with a focus on the management of skin rash and other relevant adverse events, according to the available clinical evidence. Data regarding the correlation between the development of skin rash and clinical outcome are also reported.

Expert opinion: Drugs targeting EGFR are associated with a lower overall incidence of systemic side effects compared to standard chemotherapeutic agents; nevertheless, an increased risk of distinct toxicities that may affect patient's quality of life and anticancer treatment compliance is observed. Thus, clinical training projects directed toward a more accurate knowledge of such adverse events are essential to maximize the progress of targeted therapies against cancer.

Keywords::

• adverse events
• EGFR
• management strategies
• monoclonal antibodies
• skin rash
• tyrosine kinase inhibitors

Acknowledgments

E Lucchini and S Pilotto contributed equally to this work.

Declaration of interest

This work was supported by a grant of the Italian Association for Cancer Research (AIRC IG 11930, MFAG 14282, Start-Up 10129, 5X1000 12182, 12214 and 10016) and from Italian Ministry of Education, Universities and Research (MIUR) – Interest National Research Project (PRIN-2009X23L78_005), without any implication in study design, data collection, data analysis, data interpretation or writing of the paper. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Notes

This box summarizes key points contained in the article.